Novo Nordisk appoints Anne Phillips as VP
This article was originally published in Scrip
Novo Nordisk has appointed Dr Anne Phillips as vice-president of clinical development, medical and regulatory affairs for North America. She replaces Dr Per Falk, who was promoted to senior vice-president for Novo Nordisk's biopharmaceuticals research unit in Denmark. Dr Phillips joins from GlaxoSmithKline, where she had worked within the company's R&D organisation since 1998, most recently as vice-president, medicine development leader within GSK's oncology R&D organisation. Dr Phillips will report directly to Jerzy Gruhn, president of the company's US affiliate, and senior vice-president for Novo Nordisk North America, and will serve as a member of the US executive team.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.